About NeuroKaire
NeuroKaire is a Healthcare company based in Kearny (United States) founded in 2017 by Talia Cohen Solal and Daphna Laifenfeld. Platform offering personalized treatment for psychiatric and neurological conditions. NeuroKaire has raised $20 million across 6 funding rounds from investors including European Union, GreyBird Ventures and Meron Capital. Its chief executive, as recorded, is Talia Cohen Solal. NeuroKaire offers products and services including AI Precision Platform and Drug Development Service. Its focus areas include HealthTech, Healthcare IT, Provider and Clinical Operations. Its legal entity is GenetikaPlus Ltd.
Company details
NeuroKaire was founded in 2017 in Kearny, United States, within the health technology sector focused on central nervous system disorders. A platform is operated to provide personalized treatments for psychiatric and neurological conditions. Stem cell technology, RNA expression, neurobiology, and artificial intelligence are leveraged to support precision medicine. Optimal medications for patients with depression are predicted using a blood test and questionnaire, with operations centered in the United States.
- Headquarters Kearny, United States
- Founders Talia Cohen Solal, Daphna Laifenfeld
- SectorsHealthcare
- Email••••••••
- Website neurokaire.com
- Social LinkedIn X Facebook
- Legal Name Genetikaplus Ltd
- Total Equity Funding$20M (USD)
in 6 rounds
- Latest Funding Round$10M (USD), Series A
Dec 2024
- InvestorsEuropean Union
& 7 more
Products & Services of NeuroKaire
NeuroKaire offers a comprehensive portfolio of products and services, including AI Precision Platform and Drug Development Service.
Uses AI and stem-cells for personalized psychiatry treatment predictions.
Analyzes patient-derived neurons for bio-pharma drug efficacy testing.
Funding Insights of NeuroKaire
NeuroKaire has successfully raised a total of $20M across 6 strategic funding rounds. The most recent funding activity was a Series A round of $10 million completed in December 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $20M
- Total Rounds 6
- Last Round Series A — $10M
- Investors Count 8
All 6 funding rounds of NeuroKaire with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2024 | $10M | Series A | – | GreyBird Ventures | |
| Jul 2022 | Series A | – | – | – | |
| Jul 2022 | $17.88M | Grant | – | – | |
| Jun 2022 | $2.66M | Grant | – | – | |
| Sep 2021 | $10M | Series A | – | – | |
| Jun 2018 | Grant | – | – |
8 investors in total: 6 institutional and 2 angel.
Investors in NeuroKaire
NeuroKaire has secured backing from 8 investors, including venture fund, institutional, and angel investors. Prominent investors backing the company include European Union, GreyBird Ventures and Meron Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investments are focused on precision diagnostic technologies. | greybirdventures.com | |||
Meron Capital is focused on investing in technology sectors. | meron.co | |||
No company activity is described on the website. | jumpspeed.co | |||
Deep technologies are targeted for venture capital investments. | sapirvp.com | Jerusalem, Israel | ||
Early-stage entrepreneurs are accelerated through MassChallenge's program. | masschallenge.org | Boston, United States | ||
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium | |
HM Howard Morgan | unknown_4cea52b820b3430ea | |||
MZ Michael Zeisser | unknown_8048a508d2634b64b |
Investor details for NeuroKaire
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of NeuroKaire
6 people are tracked at NeuroKaire (6 in leadership).
| Name | Role | Group |
|---|---|---|
Talia Cohen Solal | Co-Founder & CEO | Leadership |
Daphna Laifenfeld | Co-Founder | Leadership |
Michelle Yenser | Sales Director | Leadership |
David Pattison | Vice President, Business Development | Leadership |
Elad Bibi Aviv | COO | Leadership |
Issar Yazbin | Chief Product Officer | Leadership |
Complete people profiles for NeuroKaire
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of NeuroKaire
3 dated milestones of NeuroKaire across 7 years, from founding to its latest funding, stage changes and deals.
- Founded NeuroKaire is founded.
- Funding First funding round.
- Funding Latest funding round, Series A, of $10.0M.
Web traffic of NeuroKaire
The website of NeuroKaire (neurokaire.com) receives about 3.9K visits a month.
- Monthly visits3.9K
▼ 2.4% vs previous month
Top companies in Clinical IT & Data Platforms
3 companies that operate in the same segment as NeuroKaire (Clinical IT & Data Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Employee health benefits are facilitated via a cloud-based platform. | 2007 | Plymouth Meeting, Pennsylvania, United States | USD 228.3 M | |||
Healthcare appointments are booked online via Zocdoc's platform. | 2007 | New York, New York, United States | USD 425.97 M | USD 4.66 M | 1,365 | |
Virtual physical therapy and digital pain care solutions are provided. | 2015 | San Francisco, California, United States | USD 854.44 M | 1,746 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Neurokaire
Complete news archive for NeuroKaire
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about NeuroKaire
NeuroKaire was founded in 2017 and raised its 1st funding round 1 year after it was founded.
NeuroKaire is headquartered in Kearny, United States. It is registered at Kearny, New Jersey, United States.
Talia Cohen Solal is the CEO of NeuroKaire, as recorded in our data. They have also founded this company.
NeuroKaire is a funded company, having raised a total of $20M across 6 funding rounds to date.
NeuroKaire was founded in 2017 in Kearny, United States, within the health technology sector focused on central nervous system disorders. A platform is operated to provide personalized treatments for psychiatric and neurological conditions. Stem cell technology, RNA expression, neurobiology, and artificial intelligence are leveraged to support precision medicine. Optimal medications for patients with depression are predicted using a blood test and questionnaire, with operations centered in the United States.
NeuroKaire offers AI Precision Platform and Drug Development Service.
NeuroKaire has 8 investors. Key investors include European Union, GreyBird Ventures, Meron Capital, Jumpspeed, and Sapir Venture Partners.
NeuroKaire operates through Genetikaplus Ltd.